Navigation Links
OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
Date:12/20/2009

BOTHELL, WA and VANCOUVER, BC, Dec. 20 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009.

A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-747-4649 (U.S. & Canada) or 913-312-1507 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase II clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Reports Third Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
4. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
5. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
8. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
9. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
10. OncoGenex Pharmaceuticals Added to Russell Indexes
11. OncoGenex Pharmaceuticals Files Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... While things have been quiet for EcoloCap over the past ... new outlook for the future. As a continued effort to bring innovative technology ... of Mr. Siegel as CEO. With the new adjustments in management, EcoloCap has introduced ...
(Date:4/27/2017)... Md. and RESEARCH TRIANGLE PARK, ... Therapeutics Corporation (NASDAQ: UTHR ) today announced ... up to $250 million of the company,s common stock. ... open through December 31, 2017. Purchases may be made ... privately negotiated transactions from time to time as determined ...
(Date:4/27/2017)... ... 27, 2017 , ... Proscia Inc., a ... technology has the potential to eliminate subjectivity in the detection and classification of ... part of the 2017 ISBI CAMELYON Digital Pathology Challenge, organized by ...
(Date:4/27/2017)... ... April 27, 2017 , ... This month Quorum Review ... that simplifies research studies, accelerates study startup, and improves participant engagement. Developed by ... the first and only IRB-integrated eConsent solution . , “Our mission at ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):